APS_ACTION

APS ACTION is a network of internationally renown physicians & scientists working to find a cure for Antiphospholipid Syndrome or #APS

[APS_ACTION @APS_ACTION]

@APS_ACTION 2025 Young Scholar Zeynep Belce Erton from @HSpecialSurgery Presenting her Research During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan).

[APS_ACTION @APS_ACTION]

@APS_ACTION Scientific Session and Poster Presentations During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan). Thank you to all the presenters and session participants.

[APS_ACTION @APS_ACTION]

Congratulations to 2025 APSACTION Silvia Pierangeli Young Scholar Award (in collaboration with APS Foundation of America) Recipients: Alice Barinotti, Zeynep Erton, Alex Luta, Liala Moschetti, Andrew Song. During #ICAPA25, Alice and Zeynep received their certificates in person.

[APS_ACTION @APS_ACTION]

Most Recent APS ACTION Publication: https://t.co/BMUXZwH0re

[APS_ACTION @APS_ACTION]

Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION.

https://t.co/rkHBH5lKTi

[APS Support UK @APSsupportUK]

Survey Reveals 60% Satisfaction with DIAPS but Highlights Need for Improvements: https://t.co/ie5SGuuhXf @APS_ACTION @DorukErkanMD

[APS_ACTION @APS_ACTION]

2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification c… https://t.co/I3Eu8GRsAV

[APS_ACTION @APS_ACTION]

Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prosp… https://t.co/AGRGLdTAn8

[APS_ACTION @APS_ACTION]

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical … https://t.co/KdO9kecigf

[APS_ACTION @APS_ACTION]

Damage Index for Antiphospholipid Syndrome (DIAPS): An Antiphospholipid Syndrome Alliance for Clinical Trials and I… https://t.co/LjqamsK15m

[Hospital for Special Surgery (HSS) @HSpecialSurgery]

HSS investigators presented new research findings in #antiphospholipidsyndrome at the @ACRheum Convergence 2024 meeting. #ACR24 #HSSRhem @DorukErkanMD @APS_ACTION

https://t.co/B5zCydSIEl

[Jason S Knight @jasonsknight]

🤔🩸🔮
Rethinking antiphospholipid syndrome to guide future management and research
@NatRevRheumatol @DorukErkanMD
https://t.co/i9YezH8mgd

[APS_ACTION @APS_ACTION]

Our most recent publication on thrombosis recurrence and major bleeding risk in non-anticoagulated thrombotic antiphospholipid syndrome patients. We want to thank all APS ACTION members for their contributions. https://t.co/AGRGLdTAn8

[RPTH @RPTHjournal]

ICYMI: In this #RPTH Commentary @crowthrm and @DorukErkanMD discuss the new ACR/EULAR 2023 #Antiphospholipid Syndrome classification and how it may be applied across different clinical scenarios!

Read here➡️: https://t.co/w8XPEAePz5

[American College of Rheumatology @ACRheum]

#ACR23 Recap: @dorukerkanmd and @jasonsknight explained the antiphospholipid syndrome classification criteria developed by the ACR and EULAR. Read more in ACR Convergence Today → https://t.co/IiMeKjSl2U

[Doruk Erkan @DorukErkanMD]

Antiphospholipid Syndrome Diagnosis versus Classification. What is the Difference? The answer is in this recently updated @HSpecialSurgery
Top 10 Series Patient Web Article

https://t.co/BFM3LMoMda

[American College of Rheumatology @ACRheum]

Today we have award-winning #APS researcher @DorukErkanMD with us, who explains the importance of creating new classification criteria for APS & what the proper use of them ought to be! Listen → https://t.co/TU8q0CZGRm #ACR23

[APS_ACTION @APS_ACTION]

@APS_ACTION Core Laboratories Presented at #ACR23 Their Performance Assessment of LA Testing Using TSVT/ECT.

https://t.co/XrgY2AUdtT.

[APS_ACTION @APS_ACTION]

Dr Alexander Pine Presenting at #ACR23 - @APS_ACTION & Yale School of Medicine Collaboration on Antiphospholipid Syndrome and Plasma Proteomic Profiling

https://t.co/J2LpiOYxMn

[APS_ACTION @APS_ACTION]

Dr Cecile Yelnik presenting at #ACR23 on Behalf of
@APS_ACTION - Antiphospholipid Syndrome (#APS) & Complement Pathway Activation

https://t.co/bu014L5U6H.